The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors

被引:13
作者
Shen, Xianjuan [1 ]
Wang, Mei [2 ]
Guo, Yuehua [2 ]
Ju, Shaoqing [1 ]
机构
[1] Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Nantong, Peoples R China
[2] Nantong Univ, Med Off, Nantong, Peoples R China
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 25卷 / 05期
关键词
BAFF; RFQ-PCR; NHL; BAFF; STIMULATOR; BLYS;
D O I
10.17219/acem/29182
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Lymphoma is a malignant tumor of the immune system originating from lymph nodes and extra-lymphatic tissues. Its occurrence is believed to be associated with various immune cells due to the proliferation and differentiation of lymphocytes during the immune response. It has been found in many studies that B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) superfamily, could specifically activate B lymphocytes and promote their proliferation. Objectives. To explore correlations between non-Hodgkin lymphoma (NHL) and the expression of BAFF and its receptors in NHL patients. Material and Methods. The protein expression of BAFF and its receptors in serum and BAFF mRNA expression in peripheral blood mononuclear cells (PBMCs) of 47 NHL patients and 20 healthy subjects were detected by ELISA and RFQ-PCR and compared with LDH and beta(2) M levels. Results. BAFF mRNA expression in the PBMCs of NHL patients was significantly higher than in healthy controls. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in NHL patients were significantly higher than in healthy controls, and were not significantly correlated with beta(2) M and LDH levels. Conclusions. The serum protein concentration of BAFF and the expression level of BAFF mRNA in PBMCs of NHL patients underwent abnormal changes, indicating that BAFF and its receptors may play some role in the pathogenesis of NHL
引用
收藏
页码:837 / 844
页数:8
相关论文
共 50 条
[21]   Expression of B-cell activating factor (BAFF) in proliferative lupus nephritis, revisited [J].
Beltagy, Asmaa ;
Taleb, Raghda Saad Zaghloul ;
Allam, Maram ;
Abd El-Kader, Ragaa ;
Al-Girby, Amira ;
Abdelati, Abeer .
ALEXANDRIA JOURNAL OF MEDICINE, 2024, 60 (01) :147-156
[22]   Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma [J].
Lievin, Raphael ;
Hendel-Chavez, Houria ;
Balde, Aliou ;
Lancar, Remi ;
Algarte-Genin, Michele ;
Krzysiek, Roman ;
Costagliola, Dominique ;
Assoumou, Lambert ;
Taoufik, Yassine ;
Besson, Caroline .
CANCERS, 2022, 14 (01)
[23]   The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis [J].
Peveling-Oberhag, J. ;
Arcaini, L. ;
Bankov, K. ;
Zeuzem, S. ;
Herrmann, E. .
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (07) :536-544
[24]   Correlation of B-cell-activating Factor Levels and Diseases Activity in Systemic Lupus Erythematosus Patients [J].
Vitri, Ria Yolanda ;
Wachjudi, Rachmat Gunadi ;
Ghassani, Nadia Gita ;
Hamijoyo, Laniyati .
INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (01) :13-17
[25]   Elevated serum levels of B-cell activating factor in pediatric renal transplant patients [J].
Anja Lehnhardt ;
Franziska Dunst ;
Michael van Husen ;
Sebastian Loos ;
Jun Oh ;
Thomas Eiermann ;
Martina Koch ;
Markus J. Kemper .
Pediatric Nephrology, 2012, 27 :1389-1395
[26]   Cerebrospinal fluid B-cell activating factor levels as a novel biomarker in patients with neurosarcoidosis [J].
Sumi, Kaori ;
Masuda, Teruaki ;
Kimura, Noriyuki ;
Akiyoshi, Yuko ;
Obayashi, Konen ;
Matsubara, Etsuro .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 449
[27]   B-Cell Activating Factor Levels in Rheumatoid Arthritis Patients in Response to Treatment with Biologics [J].
Pyrpasopoulou, Athina ;
Balaska, Ekaterini ;
Triantafyllou, Areti ;
Anyfanti, Panagiota ;
Aslanidis, Spyros ;
Douma, Stella .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2012, 32 (07) :338-340
[28]   High B-cell activating factor levels in multi-transfused thalassemia patients [J].
Watanaboonyongcharoen, Phandee ;
Akkawat, Benjaporn ;
Tohthong, Thanida ;
Rojnuckarin, Ponlapat .
TRANSFUSION MEDICINE, 2021, 31 (05) :350-356
[29]   Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B-cell non-Hodgkin lymphoma in LMIC setting [J].
Radhakrishnan, Venkatraman ;
Kritthivasan, Venkatakrishnan ;
Kothandan, Balaji Thiruvengadam ;
Srinivasan, Prasanth ;
Das, Gargi ;
Ramamurthy, Jaikumar .
PEDIATRIC BLOOD & CANCER, 2023, 70 (12)
[30]   Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma [J].
Shi, Rong ;
Lu, Tong ;
Ku, Grace ;
Ding, Hao ;
Saito, Tomohisa ;
Gibiansky, Leonid ;
Agarwal, Priya ;
Li, Xiaobin ;
Jin, Jin Yan ;
Girish, Sandhya ;
Miles, Dale ;
Li, Chunze ;
Lu, Dan .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (03) :347-359